COSCIENS Biopharma Inc (CSCI)

[Fastmandoo]

AEterna Zentaris, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oncology and endocrine therapy focused drugs. Its product development activities focus on various therapeutic areas, mainly luteinizing hormone releasing hormone (LHRH) antagonists, and signal transduction inhibitors. The company?s lead LHRH antagonist compound is Cetrorelix, a peptide-based active substance that blocks the pituitary LHRH receptors resulting in a decrease of sex hormone levels. Cetrorelix is marketed under the brand name, Cetrotide for in vitro fertilization; and is in Phase 3 program targeting benign prostatic hyperplasia (BPH). ?terna also has a fourth generation LHRH antagonist, Ozarelix, which is in Phase 2b trials for BPH and prostate cancer. The company?s signal transduction inhibitor compound, Perifosine is in Phase 1 and Phase 2 trials for multiple cancers. It also offers Impavido, an oral therapy for visceral and cutaneous leishmaniasis, a parasitic infection. In addition, the company?s products in clinical development include ZEN-012 in Phase 1 for solid tumors and lymphoma; AN-152 in Phase 1 for breast, ovarian, and endometrial cancers; and EP-1572 in Phase 1 for growth hormone deficiencies. Further, ?terna?s products in preclinical development include Erk and PI3K inhibitors for breast, colon, lung, pancreas, melanoma, and leukemic cancers; Ghrelin receptors modulators for obesity and related pathologies; ZEN-019 for multiple cancers, BPH, and endometriosis; and Erucylphosphocholine for multiple cancers. The company sells its products primarily in the United States, Canada, Switzerland, the United Kingdom, Netherlands, and Japan. ?terna has collaborations with Merck Serono, Shionogi, Spectrum Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Solvay Pharmaceuticals, Ardana Bioscience, Roche, and Tecnofarma. The company was founded in 1990 and is headquartered in Quebec, Canada.